Pyxus Int'l Files For Chapter 11 Bankruptcy

Pyxus International Inc. (PYX) said that it filed voluntary petitions for relief under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware as part of a "prepackaged" Chapter 11 Case.

The company noted that the Chapter 11 process did not include its international subsidiaries or affiliates.

In connection with the filing, the company entered into a Restructuring Support Agreement with noteholders holding more than 92% in principal amount of the company's first lien notes and more than 67% in principal amount of its second lien notes.

As per the terms of the Restructuring Support Agreement, Pyxus' second lien noteholders will convert about $635 million of the company's debt into equity or cash, and its first lien noteholders will extend the maturity date of their existing notes by four years.

In addition, Pyxus has secured commitments for a $206.7 million Debtor-in-Possession financing facility from certain existing noteholders. The company will use proceeds from the DIP Facility to refinance the Company's existing asset-based revolver, for working capital and general corporate purposes, and to pay expenses incurred in connection with the Chapter 11 Cases.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Mallinckrodt plc announced Wednesday that the U.S. Food and Drug Administration or FDA has approved StrataGraft (allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen - dsat) for the treatment of adult patients with thermal burns containing intact dermal elements for which surgical intervention is clinically indicated. Worldwide 5G mobile subscriptions are estimated to exceed 580 million by the end of 2021, according to the Ericsson Mobility Report. With subscriptions increasing at a rate of about a million per day, 5G remains on track to become the fastest adopted mobile generation in history. The growth in subscriptions is being lead by China, North America and the Gulf Cooperation Council markets. Elanco Animal Health Inc. (ELAN) and veterinary biopharmaceutical company Kindred Biosciences, Inc. (KIN) announced Wednesday they have entered into a definitive agreement for Elanco to acquire Kindred for $9.25 per share, or approximately $440 million. The acquisition further accelerates Elanco's...
Follow RTT